High frequency of co-resistance in CTX-M-producing Escherichia coli to non-beta-lactam antibiotics, with the exceptions of amikacin, nitrofurantoin, colistin, tigecycline, and fosfomycin, in a county of Sweden

References

• Drieux L, Brossier F, Sougakoff W, Jarlier V. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide. Clin Microbiol Infect 2008;14(Suppl 1):90–103.
   PubMedGoogle Scholar
• Pitout JD, Laupland KB. Extended-spectrum beta- lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159–66.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, . CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007;59: 165–74.
   PubMed Web of Science ®Google Scholar
• Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, . Prevalence and spread of extended- spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008;14(Suppl 1):144–53.
   PubMed Web of Science ®Google Scholar
• Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008;13. pii: 19044.
   PubMedGoogle Scholar
• Bush K, Jacoby G. β-Lactamase classification and amino acid sequences for TEM, SHV. and OXA extended- spectrum. and inhibitor resistant enzymes. Lahey Clinic; 2012. Available at: http://www.lahey.org/Studies/(accessed 24 September 2012).
   Google Scholar
• Alsterlund R, Carlsson B, Gezelius L, Haeggman S, Olsson-Liljequist B. Multiresistant CTX-M-15 ESBL-producing Escherichia coli in southern Sweden: description of an outbreak. Scand J Infect Dis 2009;41:410–5.
   PubMed Web of Science ®Google Scholar
• Naseer U, Haldorsen B, Tofteland S, Hegstad K, Scheutz F, Simonsen GS, . Molecular characterization of CTX-M-15-producing clinical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. APMIS 2009;117:526–36.
   PubMed Web of Science ®Google Scholar
• Bonnedahl J, Drobni P, Johansson A, Hernandez J, Melhus Å, Stedt J, . Characterization, and comparison, of human clinical and black-headed gull (Larus ridibundus) extended-spectrum beta-lactamase-producing bacterial isolates from Kalmar, on the southeast coast of Sweden. J Antimicrob Chemother 2010;65:1939–44.
   PubMed Web of Science ®Google Scholar
• Östholm-Balkhed A, Tärnberg M, Nilsson M, Johansson AV, Hanberger H, Monstein HJ, . Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae and trends in antibiotic consumption in a county of Sweden. Scand J Infect Dis 2010;42:831–8.
   PubMed Web of Science ®Google Scholar
• Stromdahl H, Tham J, Melander E, Walder M, Edquist PJ, Odenholt I. Prevalence of faecal ESBL carriage in the community and in a hospital setting in a county of southern Sweden. Eur J Clin Microbiol Infect Dis 2011;30:1159–62.
   PubMed Web of Science ®Google Scholar
• Morosini MI, Garcia-Castillo M, Coque TM, Valverde A, Novais A, Loza E, . Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006;50:2695–9.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, de Cueto M, Rios MJ, . Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006;43:1407–14.
   PubMed Web of Science ®Google Scholar
• Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, . Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009;63:568–74.
   PubMed Web of Science ®Google Scholar
• Cavaco LM, Hansen DS, Friis-Moller A, Aarestrup FM, Hasman H, Frimodt-Moller N. First detection of plasmid-mediated quinolone resistance (qnrA and qnrS) in Escherichia coli strains isolated from humans in Scandinavia. J Antimicrob Chemother 2007;59:804–5.
   PubMed Web of Science ®Google Scholar
• Cavaco LM, Hendriksen RS, Aarestrup FM. Plasmid- mediated quinolone resistance determinant qnrS1 detected in Salmonella enterica serovar Corvallis strains isolated in Denmark and Thailand. J Antimicrob Chemother 2007;60:704–6.
   PubMed Web of Science ®Google Scholar
• Torpdahl M, Hammerum AM, Zachariasen C, Nielsen EM. Detection of qnr genes in Salmonella isolated from humans in Denmark. J Antimicrob Chemother 2009;63:406–8.
   PubMed Web of Science ®Google Scholar
• Fang H, Huang H, Shi Y, Hedin G, Nord CE, Ullberg M. Prevalence of qnr determinants among extended-spectrum beta-lactamase-positive Enterobacteriaceae clinical isolates in southern Stockholm, Sweden. Int J Antimicrob Agents 2009;34:268–70.
   PubMed Web of Science ®Google Scholar
• Gunell M, Webber MA, Kotilainen P, Lilly AJ, Caddick JM, Jalava J, . Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. Antimicrob Agents Chemother 2009;53:3832–6.
   PubMed Web of Science ®Google Scholar
• Karah N, Poirel L, Bengtsson S, Sundqvist M, Kahlmeter G, Nordmann P, . Plasmid-mediated quinolone resistance determinants qnr and aac(6′)-Ib-cr in Escherichia coli and Klebsiella spp. from Norway and Sweden. Diagn Microbiol Infect Dis 2010;66:425–31.
   PubMed Web of Science ®Google Scholar
• Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 2009;22:664–89.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez JM, Cano ME, Velasco C, Martinez-Martinez L, Pascual A. Plasmid-mediated quinolone resistance: an update. J Infect Chemother 2011;17:149–82.
   PubMed Web of Science ®Google Scholar
• Tärnberg M, Östholm-Balkhed A, Monstein HJ, Hällgren A, Hanberger H, Nilsson LE. In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2011;30:981–7.
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, v. 1.3. EUCAST; 2011. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf (accessed 24 September 2012).
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–81.
   PubMed Web of Science ®Google Scholar
• Lobel B. Short term therapy for uncomplicated urinary tract infection today.Clinical outcome upholds the theories.Int J Antimicrob Agents 2003;22(Suppl 2):85–7.
   PubMedGoogle Scholar
• Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007;29:62–5.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, . Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008;168:1897–902.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43–50.
   PubMed Web of Science ®Google Scholar
• Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2010;54:4006–8.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 2010;35:240–3.
   PubMed Web of Science ®Google Scholar
• Liu HY, Lin HC, Lin YC, Yu SH, Wu WH, Lee YJ. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect 2011; 44:364–8.
   PubMedGoogle Scholar
• Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug- resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2012;31:695–701.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005;40:1333–41.
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007;60:1206–15.
   PubMed Web of Science ®Google Scholar
• Simner PJ, Zhanel GG, Pitout J, Tailor F, McCracken M, Mulvey MR, . Prevalence and characterization of extended-spectrum beta-lactamase- and AmpC beta-lactamase-producing Escherichia coli: results of the CANWARD 2007–2009 study. Diagn Microbiol Infect Dis 2011;69:326–34.
   PubMed Web of Science ®Google Scholar
• Lu CT, Chuang YC, Sun W, Liu YC, Cheng YJ, Lu PL, . Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents 2008;32(Suppl 3):S179–83.
   Google Scholar
• Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008;62:895–904.
   PubMed Web of Science ®Google Scholar
• Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004–2007). Int J Antimicrob Agents 2009;34:121–30.
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Jones RN. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005–2009). Diagn Microbiol Infect Dis 2011;69:223–7.
   PubMed Web of Science ®Google Scholar
• Silva-Sanchez J, Reyna-Flores F, Velazquez-Meza ME, Rojas-Moreno T, Benitez-Diaz A, Sanchez-Perez A. In vitro activity of tigecycline against extended-spectrum beta-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study. Diagn Microbiol Infect Dis 2011;70:270–3.
   PubMed Web of Science ®Google Scholar
• Fraise AP. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance?J Infect 2006;53:293–300.
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, . Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011;55:5893–9.
   PubMed Web of Science ®Google Scholar
• Oteo J, Navarro C, Cercenado E, Delgado-Iribarren A, Wilhelmi I, Orden B, . Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol 2006;44:2359–66.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Villalobos H, Malaviolle V, Frankard J, de Mendonca R, Nonhoff C, Struelens MJ. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 2006;57:771–4.
   PubMed Web of Science ®Google Scholar
• Pitout JD, Le P, Church DL, Gregson DB, Laupland KB. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam. Int J Antimicrob Agents 2008;32:333–8.
   PubMed Web of Science ®Google Scholar
• Cavaco LM, Frimodt-Moller N, Hasman H, Guardabassi L, Nielsen L, Aarestrup FM. Prevalence of quinolone resistance mechanisms and associations to minimum inhibitory concentrations in quinolone-resistant Escherichia coli isolated from humans and swine in Denmark. Microb Drug Resist 2008;14:163–9.
   PubMed Web of Science ®Google Scholar
• Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat 2010;13:151–71.
   PubMed Web of Science ®Google Scholar
• Christiansen N, Nielsen L, Jakobsen L, Stegger M, Hansen LH, Frimodt-Moller N. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country. Microb Drug Resist 2011;17:395–406.
   PubMed Web of Science ®Google Scholar
• Lindemann PC, Risberg K, Wiker HG, Mylvaganam H. Aminoglycoside resistance in clinical Escherichia coli and Klebsiella pneumoniae isolates from Western Norway. APMIS 2012;120:495–502.
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. Antimicrobial wild type distributions of microorganisms. EUCAST;. Available at: http://mic.eucast.org/Eucast2/ (accessed 24 September 2012).
   Google Scholar
• Puerto AS, Fernandez JG, del Castillo Jde D, Pino MJ, Angulo GP. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli. Diagn Microbiol Infect Dis 2006;54:135–9.
   PubMed Web of Science ®Google Scholar
• Lagace-Wiens PR, Nichol KA, Nicolle LE, Decorby MR, McCracken M, Alfa MJ, . ESBL genotypes in fluoroquinolone-resistant and fluoroquinolone-susceptible ESBL-producing Escherichia coli urinary isolates in Manitoba. Can J Infect Dis Med Microbiol 2007;18:133–7.
   PubMed Web of Science ®Google Scholar
• Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR, . Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 2007;45:199–205.
   PubMed Web of Science ®Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007;20:440–58.
   PubMed Web of Science ®Google Scholar
• Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, . Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10:597–602.
   PubMed Web of Science ®Google Scholar